The European Commission has approved fam-trastuzumab deruxtecan-nxki for the treatment of patients with advanced non–small cell lung cancer whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.
Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
Patients with advanced neuroendocrine tumors who experienced progression following prior therapy experienced a significant improvement in terms of progression-free survival after treatment with cabozantinib compared with placebo.
Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.
Treatment with platinum-based chemotherapy prior to the administration of chemoradiation led to statistically significant improvements in progression-free survival and overall survival compared with chemoradiation alone in patients with locally advanced cervical cancer.
Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.
Fam-trastuzumab deruxtecan-nxki elicited responses that proved to be durable in patients with a range of solid tumors harboring HER2 mutations.
Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.
The addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Pembrolizumab plus enzalutamide provided no radiographic progression-free survival or overall survival improvements vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.
Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.
Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.
The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Treatment with the oral ALK inhibitor alectinib led to a statistically significant improvement in disease-free survival in patients with resected ALK-positive non–small cell lung cancer.
Treatment with belzutifan produced improvements in progression-free survival and objective response rate vs everolimus in patients with pretreated advanced clear cell renal cell carcinoma.
Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.
Perioperative treatment with cemiplimab continued to produce signs of efficacy in patients with resectable stage II to IV cutaneous squamous cell carcinoma.
Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.
Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease
Treatment with fam-trastuzumab deruxtecan-nxki led to sustained improvements in overall survival and progression-free survival vs physician’s choice of treatment in patients with previously treated HER2-low metastatic breast cancer, irrespective of hormone receptor status.
Fam-trastuzumab deruxtecan-nxki elicited higher rates of intracranial responses vs comparator therapies in patients with HER2-positive metastatic breast cancer with both stable and active brain metastases.
Belzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with treatment-naïve clear cell renal cell carcinoma or those who had received prior immunotherapy.
Atezolizumab plus standard-of-care platinum-based chemotherapy, followed by maintenance therapy with atezolizumab monotherapy, improved progression-free survival vs chemotherapy plus placebo, followed by placebo maintenance therapy, in the frontline treatment of patients with advanced or recurrent endometrial carcinoma particularly in those with mismatch repair–deficient disease.
Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.
